QU
uniQure
QURE · NASDAQ
$44.31 +0.37% (+$0.16)
1M -7.29%
Market Cap $3.05B
P/E Ratio -
Div. Yield -
ROE 111.96%
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 163.46x
P/B 9.42x
P/E N/A
Growth
0 /100
Declining Rev. growth 46.73%
Book val. growth 25.24%
EPS growth N/A
Profitability
7 /100
Weak Gross margin 22.79%
Net margin 1,350.73%
Op. margin 1,089.06%
Quality
0 /100
Poor ROIC 23.12%
ROE 111.96%
ROA 25.60%
Debt
69 /100
Low Debt/Equity 0.19x
Current ratio 10.01x
Int. coverage -3.28x
Stability
25 /100
Unstable Beta 0.94x
Rev. volatility 80.53%
EPS volatility 95.63%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about QURE
Online
About the company
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew C. Kapusta
Employees
221
Headquarters
Amsterdam
Upcoming events
09 NOV
Earnings
Upcoming earnings report